Waist-to-hip ratio is the most relevant obesity index at each phase of insulin secretion among obese patients.

We aimed to explore the relationship between different obesity indices and insulin secretion at each phase among obese subjects and to find out the most relevant obesity index. Height, weight, waist circumstance, and hip circumstance were obtained among 419 obese subjects to calculate body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio, body adiposity index (BAI), conicity index, abdominal volume index and a body shape index (ABSI). Fasting plasma glucose and fasting insulin were detected to calculate HOMA-ß. Early and late insulin secretion indices: ΔI30/ΔG30 and DI60-120 were calculated according to the result of a 75-g oral glucose tolerance test among the 235 subjects not meeting the standard of diabetes. Pearson correlation analysis and multiple linear regression analysis were used. BMI (ß = 0.022, p = 0.000) and WHR (ß = -1.557, p = 0.000) were independent correlation factors with HOMA-ß. In 235 OGTT subjects, WHR was independently and negatively associated with ΔI30/ΔG30 and DI60-120 (ß = -1.187, p = 0.026; ß = -1.241, p = 0.001, respectively). ABSI was independently and negatively associated with ΔI30/ΔG30 (ß = -17.249, p = 0.012). WHR was the best and consistently correlated factor with insulin secretion at each phase among obese subjects from Hunan Province in China.

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects.

1. Ginkgo biloba extract (GBE) is one of the most commonly used herbal remedies worldwide. It is usually concomitantly administrated with statins to treat diseases in geriatric patients. We aim to determine the influence of GBE on the pharmacokinetics (PK) and pharmacodynamics of simvastatin, which is currently unknown. 2. An open-label, randomized, two-period, two-treatment, balanced, crossover study was performed in 14 healthy volunteers. Subjects received simvastatin 40 mg once daily, co-treated with placebo or GBE 120 mg twice daily. Each treatment was administered for 14 d, separated by a wash-out period of 1 month. Simvastatin, simvastatin acid and lipoprotein concentrations were assessed. 3. GBE administration reduced mean simvastatin area under the curve (AUC)0-24, AUC0-∞ and Cmax by 39% (p = 0.000), 36%(p = 0.001) and 32% (p = 0.002), respectively, but did not cause significant differences in simvastatin acid PK or its cholesterol-lowering efficacy. 4. GBE consumption decreased simvastatin system exposure, but did not affect simvastatin acid PK. However, we cannot rule out the possibility for a pharmacodynamic interaction between GBE and simvastatin in vivo.